Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib.
FGFR inhibitors
cholangiocarcinoma
fibroblast growth factor receptor
infigratinib
targeted therapy
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
07
2021
accepted:
06
10
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
Cholangiocarcinoma is one of the most aggressive cancers, with a 5-year survival rate of 11-44% after surgical resection. However, there is no established systemic therapy after failure of the gemcitabine plus cisplatin first-line therapy with exception of FOLFOX. Fibroblast growth factor receptor (FGFR) genomic aberrations have been detected in cholangiocarcinoma, and targeting these genomic aberrations with FGFR inhibitors has shown remarkable clinical benefits in advanced cholangiocarcinoma. In this article, we provide up-to-date information on the clinical development of selective FGFR inhibitors in advanced cholangiocarcinoma, focusing on infigratinib. In a Phase 1 trial, infigratinib showed a safe profile. In a following Phase 2 trial, infigratinib showed remarkable efficacy in advanced cholangiocarcinoma with FGFR2 fusions or rearrangements, and the Food and Drug Administration (FDA) approved infigratinib for cholangiocarcinoma in May 2021 largely based on tumor response and duration of response. Currently infigratinib is on a Phase 3 trial (PROOF301) as a first-line setting compared to the GEMCIS therapy in advanced cholangiocarcinoma. Given that the FGFR genomic aberrations including FGFR2 fusions are rarely accompanied with other targetable mutations, infigratinib and other FGFR inhibitors are continuously expected to be the novel targeted agents in cholangiocarcinoma harboring these aberrations. Acquired resistance to infigratinib was reported in several recent studies which could potentially be a barrier to overcome. Active clinical trials including PROOF301 are expected to elucidate the clinical benefits of infigratinib in this disease. Infigratinib combined with immunotherapy is also a potential future direction of investigation in cholangiocarcinoma.
Identifiants
pubmed: 34720591
doi: 10.2147/OTT.S272208
pii: 272208
pmc: PMC8550543
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5145-5160Informations de copyright
© 2021 Yu et al.
Déclaration de conflit d'intérêts
Dr. Richard Kim received honorarium from, Incyte, QED, Lilly, BMS and Bayer, outside of the submitted work. The other authors report no conflicts of interest for this work.
Références
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872
pubmed: 29936878
Clin Cancer Res. 2015 Jun 15;21(12):2684-94
pubmed: 26078430
Sci Rep. 2019 Sep 13;9(1):13261
pubmed: 31519967
Front Oncol. 2014 Apr 14;4:64
pubmed: 24782981
Ann Oncol. 2014 Mar;25(3):552-563
pubmed: 24265351
Expert Opin Investig Drugs. 2021 Apr;30(4):317-324
pubmed: 33054456
Am J Physiol Renal Physiol. 2007 Nov;293(5):F1577-83
pubmed: 17699549
Genome Biol. 2001;2(3):REVIEWS3005
pubmed: 11276432
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Oncologist. 2012;17(1):72-9
pubmed: 22180306
Clin Cancer Res. 2019 May 1;25(9):2699-2707
pubmed: 30745300
Crit Rev Oncol Hematol. 2020 Nov;155:103091
pubmed: 32961472
Trends Genet. 2004 Nov;20(11):563-9
pubmed: 15475116
JCO Glob Oncol. 2020 Apr;6:628-638
pubmed: 32315234
J Bone Miner Res. 2011 Oct;26(10):2486-97
pubmed: 21812026
Mol Cancer Ther. 2017 Apr;16(4):614-624
pubmed: 28255027
Mol Cancer Ther. 2020 Mar;19(3):847-857
pubmed: 31911531
Hepatology. 2014 Apr;59(4):1427-34
pubmed: 24122810
PLoS One. 2020 Apr 21;15(4):e0231877
pubmed: 32315352
Int J Mol Sci. 2020 Sep 18;21(18):
pubmed: 32962091
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):221-32
pubmed: 25966423
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441-452
pubmed: 32859625
J Clin Oncol. 2017 Jan 10;35(2):157-165
pubmed: 27870574
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Ann Surg. 2006 Aug;244(2):240-7
pubmed: 16858186
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
J Med Chem. 2008 Aug 14;51(15):4632-40
pubmed: 18620382
J Med Chem. 2011 Oct 27;54(20):7066-83
pubmed: 21936542
J Clin Oncol. 2020 Jul 20;38(21):2418-2426
pubmed: 32167861
Expert Opin Investig Drugs. 2021 Apr;30(4):309-316
pubmed: 33307867
Future Oncol. 2019 Jun;15(18):2073-2082
pubmed: 31094225
Cancer Immunol Res. 2019 Sep;7(9):1457-1471
pubmed: 31331945
Ann Oncol. 2020 Oct;31(10):1405-1412
pubmed: 32622884
Cancer Treat Res Commun. 2021;27:100337
pubmed: 33611090
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
Cancer Discov. 2015 Apr;5(4):355-7
pubmed: 25847957
Future Oncol. 2020 Oct;16(30):2385-2399
pubmed: 32677452
PLoS One. 2016 Sep 14;11(9):e0162594
pubmed: 27627808
Nat Commun. 2015 Jan 22;6:6087
pubmed: 25608663
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
J Gastrointest Oncol. 2019 Aug;10(4):652-662
pubmed: 31392046
Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37
pubmed: 15863029
Mol Cancer Ther. 2014 Nov;13(11):2547-58
pubmed: 25169980
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
JCO Precis Oncol. 2018 Nov;2:1-12
pubmed: 35135097
Br J Cancer. 2017 Nov 21;117(11):1592-1599
pubmed: 28972963
Cancer Discov. 2013 Jun;3(6):636-47
pubmed: 23558953
Cancer Treat Rev. 2020 Mar;84:101974
pubmed: 32014824
Am J Physiol Renal Physiol. 2009 Aug;297(2):F282-91
pubmed: 19515808
Cancer Treat Rev. 2019 Aug;78:1-7
pubmed: 31255945
Expert Opin Investig Drugs. 2021 Apr;30(4):463-477
pubmed: 33678096
Nat Commun. 2016 Jan 04;7:10262
pubmed: 26725515
Cancer Discov. 2012 Dec;2(12):1118-33
pubmed: 23002168
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
J Hematol Oncol. 2015 May 29;8:58
pubmed: 26022204
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Crit Rev Oncol Hematol. 2017 May;113:256-267
pubmed: 28427515
Cancer Discov. 2019 Aug;9(8):1064-1079
pubmed: 31109923
Onco Targets Ther. 2021 Feb 25;14:1341-1366
pubmed: 33658799
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122
pubmed: 30367139
Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49
pubmed: 15863030
Int J Mol Med. 2016 Jul;38(1):3-15
pubmed: 27245147
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
World J Gastroenterol. 2008 Nov 14;14(42):6458-66
pubmed: 19030196
Anticancer Res. 2020 Feb;40(2):929-938
pubmed: 32014937
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
Toxicol Sci. 2012 Apr;126(2):446-56
pubmed: 22268002
Future Oncol. 2020 Oct;16(30):2375-2384
pubmed: 32580579
N Engl J Med. 1999 Oct 28;341(18):1368-78
pubmed: 10536130
ChemMedChem. 2019 Feb 19;14(4):494-500
pubmed: 30600916
Cancer Res. 2013 Nov 1;73(21):6384-8
pubmed: 24145355
Cancer Treat Rev. 2021 Apr;95:102170
pubmed: 33735689
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Cancer Res. 2020 Nov 15;80(22):4986-4997
pubmed: 32973082